Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
about
Focus on adoptive T cell transfer trials in melanomaDabrafenib: a new opportunity for the treatment of BRAF V600-positive melanomaCombining radiation and immunotherapy: a new systemic therapy for solid tumors?Systemic Therapies for Late-stage MelanomaDifferential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanomaApoptosis related protein-1 triggers melanoma cell death via interaction with the juxtamembrane region of p75 neurotrophin receptorβ-Lapachone suppresses the lung metastasis of melanoma via the MAPK signaling pathway.Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaMucosal melanomas: a case-based review of the literature.Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanomaTargeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanomaLong-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells.Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptorEvaluation of 6 Patients with Genital Melanoma from Onset of Symptoms to Death: Evaluate the Factors Affecting the Prognosis of the Disease.A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signalingA pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.Dabrafenib in metastatic melanoma: a monocentric 'real life' experience.O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasisEpigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistanceSalmonella VNP20009-mediated RNA interference of ABCB5 moderated chemoresistance of melanoma stem cell and suppressed tumor growth more potently.The Critical Role of PPARgamma in Human Malignant MelanomaCheckpoint modulation in melanoma: an update on ipilimumab and future directions.Identifying novel molecular structures for advanced melanoma by ligand-based virtual screening.Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastasesDifferential growth and responsiveness to cancer therapy of tumor cells in different environments.Metastatic melanoma - a review of current and future drugsWeight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistanceEfficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis.Current management and novel agents for malignant melanoma.Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics.Neoadjuvant treatment of melanoma: case reports and review.Dabrafenib for treatment of BRAF-mutant melanoma.Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.Standard of care in immunotherapy trials: Challenges and considerations.
P2860
Q21328679-27D12F50-3AFD-4DA7-9EEF-17B2E9B7D875Q26745933-CAF729D2-4E08-4508-B549-6CC2753C7A97Q26991721-A3326CED-B03C-42C4-9761-FAD925CB2D91Q28080215-9F0D572D-76CA-4E79-BCF8-DF3BADDBE336Q28536351-9B4F4123-DB3B-4685-9AD2-31981DF2B87AQ28661691-F00F4366-73FC-4E8C-B5FF-ABAB850B6526Q33648101-AFFD4FCD-0890-4112-A6C1-D84209B423E0Q33954883-6EC1C9B7-7174-4DDF-8551-7B7BC0A1D2D9Q34093600-44A3C669-3BD3-4B71-B244-8DB5B7031DC3Q34497045-03D024EE-A2BC-4F5D-9DF3-94D761F15981Q34620895-2CC58DDA-68F6-411B-A3A6-77E67AB05842Q35093281-1BE2831C-A708-4E90-BA94-B49C929E3CCBQ35434352-2FF8CB6C-0B91-406A-BAE0-BB0B3C50F5CAQ35584186-01304A74-4DB6-4065-94AC-9C6659D7ED54Q35835269-325BEB73-6CB8-420A-8E49-BC82470B1C45Q36014062-CEB86A85-1D7F-441C-B9C0-289F5479A3A3Q36078281-533D602E-27DB-4DE4-A3A6-32454DE4A8F1Q36264466-A0508BEA-1A40-41D0-AAB5-B3255FD198DEQ36384334-EFDEDCBA-023B-4F6E-9A5F-1BA32D875A44Q36524227-B802F9C3-56C9-4A3B-8E5B-F1A18F597B9AQ36610620-17C36D74-E847-4BBB-9F42-08FC013A30D4Q36652790-ACB544A0-EDC6-4CF9-8BE2-BE4FE097CE02Q36671260-D550C158-E0F0-47B1-BCF6-6BACC6C5C18BQ36861954-AEB4A560-BBD2-47F4-9B52-E5202861C01AQ37021699-0610D48C-B0DC-416B-A621-C46DA2BF62BBQ37046756-58B82D31-2A68-4BB9-888C-3773BE78ED73Q37165194-CD898A31-D8BC-48E1-96A8-A45F6F8279FCQ37237761-9A8F79EF-DB70-4EE9-A67D-A4D96347965CQ37363676-091A716B-D02A-45AE-9E9B-3BA31E5F3270Q37421620-31DF67B1-68D1-48F6-B29D-35C81D657E7EQ37442859-CB870D8F-DC44-4568-98D3-01E41EA5C8BAQ37450733-2E1D9510-4DFB-4427-A7CC-704C82DEA3F3Q37480946-642B42B0-3164-4733-8F6C-2BE12802FCC1Q37601946-313C88B6-B520-4516-8786-4C88BA7913F2Q37983934-599C0E4B-6D33-4610-B490-DF5FC2E2E74FQ38127412-A17B1032-1900-4021-B6CA-2AD7F269A7A2Q38185477-6703FF40-5854-4528-A009-307AB714C69EQ38187117-3C4E62F5-D6B1-44DD-B468-387CC85009F4Q38439387-5E44DD7C-30DC-4D04-8CE8-AC323E201BFFQ38749639-5F70B55B-E38B-4CA6-8A05-10A74306E1CC
P2860
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@ast
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@en
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@nl
type
label
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@ast
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@en
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@nl
prefLabel
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@ast
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@en
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@nl
P2093
P3181
P1476
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
@en
P2093
P3181
P407
P577
2000-03-01T00:00:00Z